Company news

Erasca, Inc. news

Latest news releases, newest first. Pick a year for every news release, call and deck from that year.

View company

Erasca To Host Investor Event with Leading KOL Dr. Scott Kopetz on Therapeutic Opportunities in Cancers Driven by the RAS/MAPK Pathway

April 5, 2022

Erasca Reports Fourth Quarter 2021 Financial Results and Business Updates

March 23, 2022

Erasca Announces Clinical Trial Collaboration and Supply Agreement with Eli Lilly and Company to Evaluate ERAS-007 and Cetuximab Combination

March 9, 2022

Erasca Announces Six Poster Presentations at the 2022 AACR Annual Meeting

March 7, 2022

Erasca to Present at the Guggenheim Healthcare Talks 2022 Oncology Day

February 2, 2022

Erasca Strengthens Leadership Team with Two Key Executive Appointments

January 17, 2022

Erasca to Present at the 40th Annual J.P. Morgan Healthcare Conference

January 3, 2022

Erasca Announces FDA Clearance of IND Application for ERAS-801 in Glioblastoma Multiforme and Collaboration with GCAR for Potential Inclusion in GBM AGILE Clinical Trial

December 16, 2021

Erasca Added to the Nasdaq Biotechnology Index

December 13, 2021

Erasca to Present at the Evercore ISI 4th Annual HealthCONx Conference

November 15, 2021

Erasca Reports Third Quarter 2021 Financial Results and Business Updates

November 9, 2021

Erasca Announces Presentation of Preclinical Data on ERAS-801, a CNS-Penetrant EGFR Inhibitor with Broad Activity against Oncogenic EGFR Alterations, at AACR Conference on Brain Cancer

October 24, 2021

Erasca is Named One of Fierce Biotech’s “Fierce 15” Biotechnology Companies of 2021

September 26, 2021

Erasca Announces First Patient Dosed in HERKULES-3, a Phase 1b/2 Gastrointestinal Cancer Master Protocol Evaluating ERAS-007 in Multiple Combinations

September 21, 2021

Erasca Announces First Patient Dosed in HERKULES-2 Phase 1b/2 Lung Cancer Master Protocol Evaluating ERAS-007 in Multiple Combinations

September 8, 2021

Erasca Announces Clinical Trial Collaboration and Supply Agreement with Pfizer to Evaluate ERAS-007 and Encorafenib Combination

September 7, 2021

Erasca to Participate in the Morgan Stanley 19th Annual Global Healthcare Virtual Conference

September 1, 2021

Erasca Reports Second Quarter 2021 Financial Results and Business Updates

August 25, 2021

Erasca Announces Closing of Initial Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares

July 19, 2021

Erasca Announces Pricing of Upsized Initial Public Offering

July 14, 2021

← Newer news releases

Decks

The 5 newest of 11 decks. Every deck is listed under its year.